Hypoactive Sexual Desire Disorder Clinical Trial
Official title:
The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause
Low sexual desire, or decreased libido, is one of the most prevalent sexual complaints in
females. Menopause is defined as the physiologic cessation of menses brought on by a
decrease in ovarian function and is established once menses have been absent for at least
twelve months. Perimenopause refers to the period shortly before as well as the twelve
months after the last menstrual period. The duration of perimenopause varies greatly and
signs and symptoms usually begin appearing during a woman's forties. A longitudinal study
conducted in Seattle showed that women experienced a significant reduction in sexual desire
during the late perimenopausal and early postmenopausal stages, with the biggest decline in
sexual desire occurring from three years prior to two years after the final menstrual
period. Despite being a prevalent female complaint, currently no standard treatment for low
sexual desire exists. Homeopathy may offer a safe and effective solution for this common
problem, however limited research has been conducted to date.
The aim of this study is to explore the effect of individualised homeopathic treatment on
low sexual desire in perimenopausal females using detailed case studies, the desire and
arousal subscales of the Female Sexual Function Index (FSFI) as well as Item 13 of the
Female Sexual Distress Scale - Revised (FSDS-R).
This study is an embedded mixed method case study design and will take place at the
University of Johannesburg Homeopathic Health Centre, Doornfontein Campus, over a period of
twelve weeks. These twelve weeks will consist of four consultations per participant at four
week intervals. Ten female participants aged 40-60 years who meet the inclusion criteria
will be recruited by means of advertisements placed at the University of Johannesburg
Doornfontein Campus as well as at pharmacies and health shops in the Gauteng area (with
relevant permission given).
Once the volunteers agree to participate in the study, they will be requested to sign a
Participant Information and Consent Form at the start of the initial consultation.
Participants will also be requested to complete a screening questionnaire in order to
determine whether they meet the inclusion and exclusion criteria. A complete case history
will be taken for each participant who fits the inclusion criteria, using a detailed
homeopathic case-taking form; vital signs will be checked and any necessary physical
examinations will be performed. Participants will also complete the relevant Female Sexual
Function Index (FSFI) subscales and Item 13 of the Female Sexual Distress Scale- Revised
(FSDS-R).
The appropriate individualised homeopathic remedy for each participant will be selected
using Mercurius Repertorisation Software Complete Repertory 2014 and the appropriate
homeopathic Materia Medicas, under supervision of the attending clinician. At the follow-up
consultations the case will be re-taken and the homeopathic medicine will either be repeated
or changed based on the response of the participant to the medication previously
administered following the principles of homeopathic prescribing. A relevant physical exam
will be conducted, and participants will complete the relevant subscales of the FSFI and
item 13 of the FSDS-R at each of the four consultations.
All data will be collected by the researcher during the course of the study. Qualitative
data obtained from detailed case-takings will be used to write descriptive case studies. The
FSFI subscales and FSDS-R Item 13 will be used to assess changes in desire and arousal
across time and will be represented graphically. Due to the small sample size and
qualitative nature of the cases no statistical analysis will be completed.
The outcome of this study may possibly indicate the effectiveness of individualised
homeopathic treatment in low sexual desire associated with perimenopause. This study may
provide the groundwork for future research on the effect of homeopathy on low sexual desire
in females.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02430987 -
Low Sexual Desire and Metabolic Syndrome
|
N/A | |
Completed |
NCT01432665 -
Lybrido for Female Sexual Dysfunction
|
Phase 2 | |
Terminated |
NCT00551785 -
Surveillance Study of Women Taking Intrinsa®
|
Phase 4 | |
Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
Recruiting |
NCT04179734 -
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
|
Phase 4 | |
Terminated |
NCT02770768 -
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
|
N/A | |
Completed |
NCT01235754 -
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT03287232 -
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT00384046 -
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
|
Phase 3 | |
Completed |
NCT00331123 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Recruiting |
NCT04943068 -
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
|
Phase 3 | |
Completed |
NCT03463707 -
BP101 for Adults With Female Sexual Dysfunction
|
Phase 3 | |
Completed |
NCT01208038 -
Testosterone Patch's Effects on the Cardiovascular System and Libido
|
Phase 4 | |
Completed |
NCT00657501 -
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
|
Phase 3 | |
Completed |
NCT04336891 -
Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
|
||
Completed |
NCT01382719 -
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
|
Phase 2 | |
Recruiting |
NCT00916396 -
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
|
N/A | |
Completed |
NCT00331214 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT00338312 -
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 |